ECSP19026563A - Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos - Google Patents
Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismosInfo
- Publication number
- ECSP19026563A ECSP19026563A ECSENADI201926563A ECDI201926563A ECSP19026563A EC SP19026563 A ECSP19026563 A EC SP19026563A EC SENADI201926563 A ECSENADI201926563 A EC SENADI201926563A EC DI201926563 A ECDI201926563 A EC DI201926563A EC SP19026563 A ECSP19026563 A EC SP19026563A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- pyrimidin
- amine
- pyrazole
- prophylaxis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención se refiere a compuestos sustituidos de 6-(1H-pirazol-1-il)pirimidin-4-amina de la fórmula general (I) tal como se describen y definen en el presente, procedimientos para preparar dichos compuestos, compuestos de productos intermedios útiles para preparar dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden dichos compuestos, y el uso de dichos compuestos para la fabricación de composiciones farmacéuticas para el tratamiento o profilaxis de enfermedades, en particular para el tratamiento y/o profilaxis de enfermedades cardiovasculares y renales ,como agente único o en combinación con otros compuestos activos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16193953 | 2016-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP19026563A true ECSP19026563A (es) | 2019-04-30 |
Family
ID=57136772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI201926563A ECSP19026563A (es) | 2016-10-14 | 2019-04-12 | Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos |
Country Status (28)
Country | Link |
---|---|
US (2) | US11208400B2 (es) |
EP (1) | EP3526212B1 (es) |
JP (1) | JP2019532961A (es) |
KR (1) | KR20190065402A (es) |
CN (1) | CN110191884A (es) |
AR (1) | AR109947A1 (es) |
AU (1) | AU2017341324A1 (es) |
BR (1) | BR112019007496A2 (es) |
CA (1) | CA3040166A1 (es) |
CL (1) | CL2019001004A1 (es) |
CO (1) | CO2019003761A2 (es) |
CR (1) | CR20190192A (es) |
CU (1) | CU24518B1 (es) |
DO (1) | DOP2019000099A (es) |
EA (1) | EA201990947A1 (es) |
EC (1) | ECSP19026563A (es) |
GE (1) | GEP20217269B (es) |
IL (1) | IL265923A (es) |
JO (1) | JOP20190080A1 (es) |
MA (1) | MA46514A (es) |
MX (1) | MX2019004347A (es) |
PE (1) | PE20191549A1 (es) |
PH (1) | PH12019500808A1 (es) |
SG (1) | SG11201903305XA (es) |
TN (1) | TN2019000114A1 (es) |
TW (1) | TW201825477A (es) |
UY (1) | UY37444A (es) |
WO (1) | WO2018069222A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110734428A (zh) * | 2019-10-24 | 2020-01-31 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物 |
CN115403524A (zh) * | 2021-05-26 | 2022-11-29 | 浙江省化工研究院有限公司 | 3-氟代吡唑羧酸酯、3-氟代烷基-1-取代吡唑-4-羧酸的制备方法 |
WO2024061768A1 (en) | 2022-09-19 | 2024-03-28 | Basf Se | Azole pesticidal compounds |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3966781A (en) | 1970-12-17 | 1976-06-29 | Merck Sharp & Dohme (I.A.) Corporation | Deuteration of functional group-containing hydrocarbons |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
WO2000043402A2 (en) | 1999-01-21 | 2000-07-27 | Board Of Regents, The University Of Texas System | Inhibitors of intestinal apical membrane na/phosphate co-transportation |
DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
US7119120B2 (en) | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
DE102008020113A1 (de) * | 2008-04-23 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dihydropyrazolone und ihre Verwendung |
ATE519759T1 (de) | 2004-12-30 | 2011-08-15 | Exelixis Inc | Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren |
CA2684240A1 (en) * | 2007-04-16 | 2008-10-30 | Serenex, Inc. | Tetrahydroindole and tetrahydroindazole derivatives |
JP2008296610A (ja) | 2007-05-29 | 2008-12-11 | Toyota Motor Corp | 車両用動力伝達装置の制御装置 |
KR101660544B1 (ko) * | 2008-04-29 | 2016-09-27 | 노파르티스 아게 | 섬유모세포 성장 인자 수용체의 키나제 활성에 대한 조정을 모니터링하는 방법 및 상기 방법의 용도 |
CN102264737A (zh) | 2008-12-23 | 2011-11-30 | 雅培制药有限公司 | 抗病毒化合物 |
DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
MX2012009862A (es) | 2010-02-27 | 2012-09-12 | Bayer Ip Gmbh | Ariltriazolonas ligadas a bisarilo y su uso. |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
JP5860459B2 (ja) | 2010-06-30 | 2016-02-16 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | sGC刺激薬 |
WO2012006475A1 (en) * | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
JP5823514B2 (ja) | 2010-07-07 | 2015-11-25 | アーデリクス,インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
JP5827326B2 (ja) | 2010-07-07 | 2015-12-02 | アーデリクス,インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
JP5827328B2 (ja) | 2010-07-07 | 2015-12-02 | アーデリクス,インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
WO2012006474A2 (en) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
EP2590979A1 (de) | 2010-07-09 | 2013-05-15 | Bayer Intellectual Property GmbH | Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
EP2675440B1 (en) | 2011-02-14 | 2020-03-25 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
AU2012329913A1 (en) | 2011-10-27 | 2014-05-22 | Astellas Pharma Inc. | Aminoalkyl-substituted N-thienyl benzamide derivative |
WO2013082756A1 (en) | 2011-12-06 | 2013-06-13 | Leo Pharma A/S | Phosphate transport inhibitors ii |
US10150742B2 (en) | 2013-03-15 | 2018-12-11 | President And Fellows Of Harvard College | Substituted heterocyclic compounds for treating or preventing viral infections |
WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
JO3336B1 (ar) | 2014-10-07 | 2019-03-13 | Lilly Co Eli | مركبات أمينو بيريديلوكسي بيرازول |
AR102487A1 (es) | 2014-11-03 | 2017-03-01 | Bayer Pharma AG | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos |
CN105631664A (zh) | 2014-11-26 | 2016-06-01 | 华为终端(东莞)有限公司 | 一种非接触支付方法、装置及系统 |
CN107406442B (zh) * | 2014-12-23 | 2021-08-17 | 达纳-法伯癌症研究所公司 | 作为egfr抑制剂的新的嘧啶和治疗病症的方法 |
EP3878456B1 (en) | 2016-10-14 | 2023-03-15 | Institut Pasteur De Montevideo | Pluripotent anti-inflammatory and metabolic modulators for the treatment of obesity |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
CN109843880B (zh) | 2016-10-14 | 2023-12-01 | 诺华股份有限公司 | 4-(2-((1r,2r)-2-羟基环己基氨基)苯并噻唑-6-基氧基)-n-甲基吡啶酰胺的晶型 |
-
2017
- 2017-06-16 JO JOP/2019/0080A patent/JOP20190080A1/ar unknown
- 2017-10-09 CA CA3040166A patent/CA3040166A1/en active Pending
- 2017-10-09 SG SG11201903305XA patent/SG11201903305XA/en unknown
- 2017-10-09 AU AU2017341324A patent/AU2017341324A1/en not_active Abandoned
- 2017-10-09 MX MX2019004347A patent/MX2019004347A/es unknown
- 2017-10-09 EP EP17780751.8A patent/EP3526212B1/en active Active
- 2017-10-09 CN CN201780074126.5A patent/CN110191884A/zh active Pending
- 2017-10-09 US US16/341,410 patent/US11208400B2/en active Active
- 2017-10-09 CU CU2019000035A patent/CU24518B1/es unknown
- 2017-10-09 EA EA201990947A patent/EA201990947A1/ru unknown
- 2017-10-09 MA MA046514A patent/MA46514A/fr unknown
- 2017-10-09 TN TNP/2019/000114A patent/TN2019000114A1/en unknown
- 2017-10-09 PE PE2019000822A patent/PE20191549A1/es unknown
- 2017-10-09 KR KR1020197013647A patent/KR20190065402A/ko not_active Application Discontinuation
- 2017-10-09 CR CR20190192A patent/CR20190192A/es unknown
- 2017-10-09 BR BR112019007496A patent/BR112019007496A2/pt not_active Application Discontinuation
- 2017-10-09 GE GEAP201715076A patent/GEP20217269B/en unknown
- 2017-10-09 JP JP2019519748A patent/JP2019532961A/ja active Pending
- 2017-10-09 WO PCT/EP2017/075630 patent/WO2018069222A1/en unknown
- 2017-10-12 TW TW106134859A patent/TW201825477A/zh unknown
- 2017-10-13 UY UY0001037444A patent/UY37444A/es not_active Application Discontinuation
- 2017-10-13 AR ARP170102862A patent/AR109947A1/es unknown
-
2019
- 2019-04-08 IL IL265923A patent/IL265923A/en unknown
- 2019-04-12 CL CL2019001004A patent/CL2019001004A1/es unknown
- 2019-04-12 DO DO2019000099A patent/DOP2019000099A/es unknown
- 2019-04-12 PH PH12019500808A patent/PH12019500808A1/en unknown
- 2019-04-12 EC ECSENADI201926563A patent/ECSP19026563A/es unknown
- 2019-04-12 CO CONC2019/0003761A patent/CO2019003761A2/es unknown
-
2021
- 2021-11-04 US US17/519,329 patent/US20230065629A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
GEP20217269B (en) | 2021-06-25 |
PH12019500808A1 (en) | 2020-01-20 |
TN2019000114A1 (en) | 2020-10-05 |
UY37444A (es) | 2018-05-31 |
US11208400B2 (en) | 2021-12-28 |
JOP20190080A1 (ar) | 2019-04-11 |
WO2018069222A1 (en) | 2018-04-19 |
BR112019007496A2 (pt) | 2019-09-10 |
CL2019001004A1 (es) | 2019-08-30 |
CU24518B1 (es) | 2021-06-08 |
CO2019003761A2 (es) | 2019-04-30 |
EP3526212A1 (en) | 2019-08-21 |
US20230065629A1 (en) | 2023-03-02 |
KR20190065402A (ko) | 2019-06-11 |
SG11201903305XA (en) | 2019-05-30 |
AR109947A1 (es) | 2019-02-06 |
EA201990947A1 (ru) | 2019-08-30 |
MA46514A (fr) | 2019-08-21 |
IL265923A (en) | 2019-06-30 |
CN110191884A (zh) | 2019-08-30 |
AU2017341324A1 (en) | 2019-05-02 |
PE20191549A1 (es) | 2019-10-24 |
US20200055842A1 (en) | 2020-02-20 |
CR20190192A (es) | 2019-09-02 |
EP3526212B1 (en) | 2021-12-22 |
MX2019004347A (es) | 2019-07-01 |
DOP2019000099A (es) | 2019-07-15 |
JP2019532961A (ja) | 2019-11-14 |
TW201825477A (zh) | 2018-07-16 |
CU20190035A7 (es) | 2019-11-04 |
CA3040166A1 (en) | 2018-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019004137A2 (es) | 1,2,4–triazolonas 2,4,5–trisustituidas | |
CL2017002650A1 (es) | Compuestos novedosos | |
NI201700095A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
ECSP17007538A (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
NI201800128A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
UY35040A (es) | Pirrolopirimidinilamino-benzotiazolonas sustituidas | |
CU20130033A7 (es) | Imidazopiridazinas sustituidas | |
CR20140113A (es) | Imidazopiridazinas sustituidas con amino | |
CO2017005968A2 (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
PE20151759A1 (es) | Imidazopiridazinas sustituidas | |
NI201600006A (es) | Pirazolo-piridinaminas sustituidas | |
CU20160072A7 (es) | Tienopirimidinas como inhibidores mknk1 y mknk2 | |
CU20200008A7 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen | |
ECSP19026563A (es) | Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos | |
DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
GT201700126A (es) | Ácidos piridil-cicloalquil-carboxílicos sustituidos composiciones que los contienen y usos de los mismos | |
DOP2019000221A (es) | Derivados de pirazol como inhibidores de bromodominio | |
CU24283B1 (es) | Composiciones farmacéuticas | |
UY37032A (es) | Compuestos de heteroarilbenzimidazol | |
UY36983A (es) | Pirazolopiridinaminas sustituidas | |
UY34630A (es) | Imidazopiridazinas sustituidas con amino |